Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Creators
- She, Qing-Bai1, 2, 3
- Gruvberger-Saal, Sofia K.4, 5
- Maurer, Matthew6, 7
- Chen, Yilun5
- Jumppanen, Mervi8
- Su, Tao7
- Dendy, Meaghan4
- Lau, Ying-Ka Ingar7
- Memeo, Lorenzo9
- Horlings, Hugo M.10
- Vijver, Marc J. van de11
- Isola, Jorma12
- Hibshoosh, Hanina13, 7
- Rosen, Neal3
- Parsons, Ramon14, 13, 6, 4
- Saal, Lao H.15, 4, 5
- 1. Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY (United States)
- 2. Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY (United States)
- 3. Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- 4. Institute for Cancer Genetics, Columbia University Medical Center, New York, NY (United States)
- 5. Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund (Sweden)
- 6. Department of Medicine, Columbia University, New York, NY (United States)
- 7. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY (United States)
- 8. Department of Pathology, Seinäjoki Central Hospital, Seinäjoki (Finland)
- 9. Department of Experimental Oncology, Mediterranean Institute of Oncology, Catania (Italy)
- 10. Department of Pathology, Netherlands Cancer Institute, Amsterdam (Netherlands)
- 11. Department of Pathology, Academic Medical Center, Amsterdam (Netherlands)
- 12. Institute of Medical Technology, University of Tampere, Tampere (Finland)
- 13. Department of Pathology, Columbia University, New York, NY (United States)
- 14. Department of Oncological Sciences and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (United States)
- 15. Translational Oncogenomics Unit, Division of Oncology and Pathology, Lund University Cancer Center, Medicon Village 404-B2, SE-22381 Lund (Sweden)
Description
The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted therapies. The oncogenic signaling pathways driving basal-like tumorigenesis are not fully elucidated. One hundred sixteen unselected breast tumors were subjected to integrated analysis of phosphoinositide 3-kinase (PI3K) pathway related molecular aberrations by immunohistochemistry, mutation analysis, and gene expression profiling. Incidence and relationships between molecular biomarkers were characterized. Findings for select biomarkers were validated in an independent series. Synergistic cell killing in vitro and in vivo tumor therapy was investigated in breast cancer cell lines and mouse xenograft models, respectively. Sixty-four % of cases had an oncogenic alteration to PIK3CA, PTEN, or INPP4B; when including upstream kinases HER2 and EGFR, 75 % of cases had one or more aberration including 97 % of estrogen receptor (ER)-negative tumors. PTEN-loss was significantly associated to stathmin and EGFR overexpression, positivity for the BLBC markers cytokeratin 5/14, and the BLBC molecular subtype by gene expression profiling, informing a potential therapeutic combination targeting these pathways in BLBC. Combination treatment of BLBC cell lines with the EGFR-inhibitor gefitinib plus the PI3K pathway inhibitor LY294002 was synergistic, and correspondingly, in an in vivo BLBC xenograft mouse model, gefitinib plus PI3K-inhibitor PWT-458 was more effective than either monotherapy and caused tumor regression. Our study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast cancer and supports the future clinical evaluation of combining EGFR and PI3K pathway inhibitors for the treatment of BLBC. The online version of this article (doi:10.1186/s12885-016-2609-2) contains supplementary material, which is available to authorized users
Availability note (English)
Available from http://dx.doi.org/10.1186/s12885-016-2609-2; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971667Additional details
Identifiers
Publishing Information
- Journal Title
- BMC cancer (Online)
- Journal Volume
- 16
- Journal Page Range
- vp.
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47088254
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOLOGICAL MARKERS; CELL KILLING; IN VITRO; IN VIVO; MAMMARY GLANDS; NEOPLASMS; THERAPY
- Descriptors DEC
- BODY; DISEASES; GLANDS; MEDICINE; ORGANS
Optional Information
- Copyright
- Copyright (c) The Author(s). 2016
- Notes
- PMCID: PMC4971667; PMID: 27484095; PUBLISHER-ID: 2609; OAI: oai:pubmedcentral.nih.gov:4971667